Date Filed | Type | Description |
06/09/2023 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Granted 3,860 shares
@ $0 Disposed/sold 3,300 shares
@ $51.82, valued at
$171k
Granted 7,110 options to buy
@ $51.82, valued at
$368.4k
|
|
06/02/2023 |
4
| Fust Matthew K (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.
Txns:
| Granted 57,000 shares
@ $0 Granted 79,500 options to buy
@ $1.53, valued at
$121.6k
|
|
07/15/2022 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 5,700 shares
@ $20.957, valued at
$119.5k
Exercised 5,700 options to buy
@ $1.45, valued at
$8.3k
|
|
06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/21/2022 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Granted 17,500 options to buy
@ $18.29, valued at
$320.1k
|
|
03/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/05/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.
Txns:
| Sold 13,354 shares
@ $19.5, valued at
$260.4k
|
|
11/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/09/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 6,046 shares
@ $25.5, valued at
$154.2k
Exercised 6,046 options to buy
@ $1.91, valued at
$11.5k
|
|
07/27/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 5,000 shares
@ $19.59, valued at
$98k
Exercised 5,000 options to buy
@ $1.91, valued at
$9.6k
|
|
07/20/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 5,000 shares
@ $19.5, valued at
$97.5k
Exercised 5,000 options to buy
@ $1.91, valued at
$9.6k
|
|
07/13/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 5,000 shares
@ $20.71, valued at
$103.6k
Exercised 5,000 options to buy
@ $1.91, valued at
$9.6k
|
|
06/28/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Granted 2,145 shares
@ $0 Granted 4,125 options to buy
@ $93.2, valued at
$384.5k
|
|
06/23/2021 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Granted 17,500 options to buy
@ $20.23, valued at
$354k
|
|
06/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/08/2020 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Sold 6,181 shares
@ $90, valued at
$556.3k
Exercised 6,181 options to buy
@ $21, valued at
$129.8k
|
|
07/06/2020 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Sold 5,000 shares
@ $85, valued at
$425k
Exercised 5,000 options to buy
@ $21, valued at
$105k
|
|
06/30/2020 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Granted 2,550 shares
@ $0 Granted 4,250 options to buy
@ $76.58, valued at
$325.5k
|
|
06/22/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/17/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/19/2020 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Sold 1,875 shares
@ $75, valued at
$140.6k
|
|
04/24/2020 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Sold 1,875 shares
@ $65, valued at
$121.9k
|
|
02/24/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/26/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Dermira, Inc.
Txns:
| Sold 3,000 shares
@ $15, valued at
$45k
|
|
12/18/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Sold 3,500 shares
@ $22.5, valued at
$78.8k
Exercised 3,500 options to buy
@ $1.91, valued at
$6.7k
|
|
12/13/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Dermira, Inc.
Txns:
| Sold 3,000 shares
@ $12, valued at
$36k
|
|
09/16/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Dermira, Inc.
Txns:
| Sold 6,000 shares
@ $8.7727, valued at
$52.6k
|
|
07/01/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Atara Biotherapeutics, Inc.
Txns:
| Granted 4,000 shares
@ $0 Granted 13,000 options to buy
@ $20.25, valued at
$263.3k
|
|
06/25/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
Txns:
| Granted 12,500 options to buy
@ $23.24, valued at
$290.5k
|
|
06/14/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Dermira, Inc.
Txns:
| Exercised 3,000 options to buy
@ $0 |
|
06/13/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 5,000 options to buy
@ $58.74, valued at
$293.7k
|
|
06/06/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on Dermira, Inc.
Txns:
| Granted 6,000 options to buy
@ $9.38, valued at
$56.3k
Granted 3,000 restricted stock units
@ $0 |
|
05/20/2019 |
4
| Fust Matthew K (Director) has filed a Form 4 on MACROGENICS INC
Txns:
| Granted 10,000 options to buy
@ $18, valued at
$180k
|
|
|